- Home
- LNSR vs MGX Comparison
LNSR vs MGX Comparison
Compare LNSR & MGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNSR
- MGX
- Stock Information
- Founded
- LNSR 2004
- MGX 2018
- Country
- LNSR United States
- MGX United States
- Employees
- LNSR N/A
- MGX N/A
- Industry
- LNSR Medical Electronics
- MGX
- Sector
- LNSR Health Care
- MGX
- Exchange
- LNSR Nasdaq
- MGX NYSE
- Market Cap
- LNSR N/A
- MGX 62.1M
- IPO Year
- LNSR N/A
- MGX 2024
- Fundamental
- Price
- LNSR $12.90
- MGX $2.08
- Analyst Decision
- LNSR Hold
- MGX Strong Buy
- Analyst Count
- LNSR 1
- MGX 4
- Target Price
- LNSR $15.00
- MGX $13.00
- AVG Volume (30 Days)
- LNSR 153.4K
- MGX 916.2K
- Earning Date
- LNSR 08-07-2025
- MGX 08-13-2025
- Dividend Yield
- LNSR N/A
- MGX N/A
- EPS Growth
- LNSR N/A
- MGX N/A
- EPS
- LNSR N/A
- MGX N/A
- Revenue
- LNSR $57,065,000.00
- MGX $45,263,000.00
- Revenue This Year
- LNSR $29.95
- MGX N/A
- Revenue Next Year
- LNSR $29.35
- MGX $11.75
- P/E Ratio
- LNSR N/A
- MGX N/A
- Revenue Growth
- LNSR 28.24
- MGX N/A
- 52 Week Low
- LNSR $3.50
- MGX $1.23
- 52 Week High
- LNSR $17.31
- MGX $5.49
- Technical
- Relative Strength Index (RSI)
- LNSR 47.89
- MGX 62.36
- Support Level
- LNSR $12.77
- MGX $2.04
- Resistance Level
- LNSR $13.47
- MGX $2.47
- Average True Range (ATR)
- LNSR 0.35
- MGX 0.18
- MACD
- LNSR 0.05
- MGX 0.07
- Stochastic Oscillator
- LNSR 45.71
- MGX 61.76
About MGX METAGENOMI INC
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.